United States

BioLine RX Ltd (BLRX.OQ)

BLRX.OQ on NASDAQ Stock Exchange Capital Market

22 Jul 2016
Change (% chg)

$0.01 (+1.29%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for BLRX.OQ


BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in... (more)


No Ratios Available.


  BLRX.OQ Industry Sector
P/E (TTM): -- 41.38 36.72
EPS (TTM): -- -- --
ROI: -- -5.08 14.32
ROE: -- -3.41 15.54

BRIEF-BioLineRx reports net loss for Q1 of $3.5 mln

* Net loss for three months ended March 31, 2016 amounted to $3.5 million , compared with a net loss of $4.3 million Source text for Eikon:

May 17 2016

BRIEF-Bioline RX, Omega Pharma received European approval for bl-5010 as treatment for non-surgical removal of skin lesions

* Omega pharma received ce mark approval for bl-5010 as a novel otc treatment for non-surgical removal of skin lesions Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Apr 04 2016

BRIEF-Biolinerx reports successful top-line phase 2 trial results

* Successful results in phase 2 trial for AML data identify a potential biomarker for future selection of BL-8040-responsive AML patients

Mar 29 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : ValuEngine, Inc.
Provider : Reuters Investment Profile
Provider : GlobalData
Provider : Pechala's Reports
Provider : GlobalData

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.